INM · NASDAQ
InMed Pharmaceuticals (INM) Stock Price & Fundamentals
InMed Pharmaceuticals (INM) closed at $694.55 on Oct 9, 2026, up 0.50% from the previous close of $691.08.
Share price, past year
1Y −7.09%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $694.55 |
| Sep 30, 2026 | $701.36 |
| Aug 31, 2026 | $756.94 |
| Jul 31, 2026 | $729.12 |
| Jun 30, 2026 | $698.38 |
| May 29, 2026 | $707.63 |
| Apr 30, 2026 | $721.25 |
| Mar 31, 2026 | $733.56 |
| Feb 27, 2026 | $728.99 |
| Jan 30, 2026 | $779.23 |
| Dec 31, 2025 | $696.82 |
| Nov 28, 2025 | $710.68 |
| Oct 31, 2025 | $729.06 |
Key statistics
- Market cap
- $3.71B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.12
- Revenue (TTM)
- $4.51M
- Net income (TTM)
- −$12.56M
- Shares outstanding
- 5.3M
- Dividend yield
- —
- 52-week range
- $662.96 – $779.23
InMed Pharmaceuticals's market cap is $3.71B, based on a share price of $694.55 and 5.3M shares outstanding as of Jun 30, 2026.
Financials
InMed Pharmaceuticals reported revenue of $4.94M for fiscal 2025, up 7.50% from fiscal 2024.
InMed Pharmaceuticals reported a net loss of $12.56M in fiscal 2026.
Fiscal 2025 revenue was the highest in the 5 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Jun 30, 2025 | $4.94M | +7.5% | −$8.16M | −165.1% | −$8.36 | — |
| FY2024ended Jun 30, 2024 | $4.60M | +11.2% | −$7.68M | −166.9% | −$20.14 | −$7.00M |
| FY2023ended Jun 30, 2023 | $4.14M | +279.6% | −$7.95M | −192.2% | −$3.25 | −$7.44M |
| FY2022ended Jun 30, 2022 | $1.09M | −42.8% | −$18.60M | −1,707.3% | −$33.17 | −$15.62M |
| FY2021ended Jun 30, 2021 | $1.90M | — | −$10.20M | −535.9% | −$37.96 | −$9.79M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Dec 31, 2025 | $820.19K | −$2.03M | −$0.51 |
| Q1 FY2026ended Sep 30, 2025 | $1.12M | −$1.73M | −$0.44 |
| Q4 FY2025ended Jun 30, 2025 | $1.30M | −$1.79M | −$0.07 |
| Q3 FY2025ended Mar 31, 2025 | $1.26M | −$2.12M | −$1.94 |
| Q2 FY2025ended Dec 31, 2024 | $1.11M | −$2.58M | −$3.64 |
| Q1 FY2025ended Sep 30, 2024 | $1.26M | −$1.68M | −$2.71 |
| Q4 FY2024ended Jun 30, 2024 | $1.28M | — | — |
| Q3 FY2024ended Mar 31, 2024 | $1.17M | — | — |
Company profile
- Name
- InMed Pharmaceuticals Inc.
- Ticker
- INM
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- C/O Norton Rose Fulbright Canada Llp, Suite 1800 - 510 West Georgia Street, Vancouver, V6B 0M3
- Incorporated in
- A1
- Fiscal year ends
- June
- SEC CIK
- 0001728328
Recent SEC filings
- Sep 18, 2026
- Sep 9, 2026
- Jul 22, 2026
- Jul 10, 2026
- Jun 10, 2026
- May 19, 2026
- May 19, 2026
- May 7, 2026
Frequently asked questions
What is InMed Pharmaceuticals's stock price?
InMed Pharmaceuticals (INM) closed at $694.55 on Oct 9, 2026, up 0.50% from the previous close of $691.08.
What is InMed Pharmaceuticals's market cap?
InMed Pharmaceuticals's market cap is $3.71B, based on a share price of $694.55 and 5.3M shares outstanding as of Jun 30, 2026.
How much revenue does InMed Pharmaceuticals make?
InMed Pharmaceuticals reported revenue of $4.94M for fiscal 2025, up 7.50% from fiscal 2024.
Does InMed Pharmaceuticals pay a dividend?
InMed Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from InMed Pharmaceuticals Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures